Políticas Médicas
Las políticas médicas son documentos que definen el reconocimiento de cubierta para tecnologías, procedimientos y tratamientos. Las declaraciones de necesidad médica en las políticas, sobre si una tecnología, procedimiento, tratamiento, suplido, equipo, medicamento u otro servicio mejora el resultado en la salud de la población para la cual dicha tecnología o tratamiento fue diseñado se basan en evidencia científica, estudios clínicos y opiniones profesionales de nuestros proveedores y de las organizaciones médicas reconocidas.
Cada documento desplegado en este sitio Web se provee con propósitos informativos solamente y no es una autorización, explicación de beneficios o un contrato. El recibir beneficios está sujeto a la satisfacción de todos los términos y condiciones de la cubierta. La tecnología médica cambia constantemente y nos reservamos el derecho de revisar y actualizar nuestras políticas periódicamente.
| ID | Título | Última Revisión | Siguiente Revisión | Descripción | Acceso |
|---|---|---|---|---|---|
| 05.001.044 | Polivy® (polatuzumab vedotin-piiq) | Sep 25, 2025 | Sep 20, 2026 | Polivy® (polatuzumab vedotin-piiq) is an antibody-drug conjugate directed against cd79b. it is... | Ver |
| 05.001.045 | Lumasiran For Primary Hyperoxaluria Type 1 | Aug 09, 2025 | Aug 20, 2026 | Primary hyperoxalurias are a group of rare genetic diseases. there are 3 subtypes each resulting in the... | Ver |
| 05.001.046 | Monoclonal Antibodies for Treatment of Alzheimer Disease | Aug 27, 2024 | Policy Archived | Alzheimer disease (ad) is a neurodegenerative disorder leading to progressive, irreversible destruction of... | Ver |
| 05.001.047 | Fibrin Sealant | Sep 25, 2025 | Sep 20, 2026 | ... | Ver |
| 05.001.048 | Biological Treatments for Refractory Myasthenia Gravis | Jul 11, 2025 | Jul 20, 2026 | Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fluctuating motor weakness... | Ver |
| 05.001.049 | Givosiran for Acute Hepatic Porphyria | Oct 23, 2024 | Oct 20, 2025 | Acute hepatic porphyria (ahp) is a rare disease with a prevalence of 5 to 10 cases/100,000 people in the us... | Ver |
| 05.001.050 | Omidubicel as Adjunct Treatment for Hematologic Malignancies | Oct 08, 2025 | Oct 20, 2026 | Hematologic malignancies are a heterogeneous group of diseases characterized by distinct biological subtypes,... | Ver |
| 05.001.051 | Pharmacologic Treatments for Metabolic Dysfunction-Associated Steatohepatitis | Nov 13, 2025 | Nov 20, 2026 | Metabolic dysfunction-associated steatohepatitis (mash), formerly known as non-alcoholic steatohepatitis... | Ver |
| 05.001.052 | Tofersen (Qalsody) | Sep 25, 2025 | Sep 20, 2026 | Tofersen (qalsody) is an antisense oligonucleotide indicated for the treatment of amyotrophic lateral... | Ver |
| 05.001.053 | Mitotic Inhibitors | Sep 25, 2025 | Sep 20, 2026 | Mitotic inhibitors (paclitaxel, docetaxel, abraxane) are chemotherapy agents used in multiple solid tumors,... | Ver |
| 05.002.001 | Chimeric Antigen Receptor Therapy For Multiple Myeloma | Aug 12, 2025 | Aug 20, 2026 | Multiple myeloma is a hematologic malignancy characterized by abnormal growth of plasma cells with production... | Ver |
| 05.003.001 | Gene Therapies for Thalassemia | Apr 21, 2025 | Apr 20, 2026 | Beta (β)-thalassemia is a genetic hemoglobinopathy that results from defects in β-globin synthesis... | Ver |
| 05.003.002 | Gene Therapies for Sickle Cell Disease | Apr 22, 2025 | Apr 20, 2026 | Sickle cell disease is a genetic hemoglobinopathy that results from a genetic variant in the hbb gene... | Ver |
| 05.003.003 | Gene Therapies for Metachromatic Leukodystrophy | Jul 15, 2025 | Jul 20, 2026 | Metachromatic leukodystrophy (mld) is a rare autosomal recessive lysosomal storage disorder. it arises due to... | Ver |
| 05.003.004 | Gene Therapies for Duchenne Muscular Dystrophy | Oct 16, 2024 | Oct 20, 2025 | Duchenne muscular dystrophy (dmd) is an inherited disorder that results in progressive muscle weakness and... | Ver |
| 05.003.005 | Gene Therapies for Congenital Hemophilia A or B | Jan 30, 2025 | Oct 20, 2025 | Most commonly, hemophilia is a recessive x-linked congenital bleeding disorder that predominantly affects... | Ver |
| 05.003.007 | Gene Therapies for Aromatic L-amino Acid Decarboxylase Deficiency | Sep 22, 2025 | Sep 20, 2026 | Aromatic l-amino acid decarboxylase (aadc) deficiency is a rare autosomal recessive neurodevelopmental... | Ver |
| 06.001.001 | Doppler Transcraneal | Jun 23, 2017 | Policy Archived | ... | Ver |
| 06.001.002 | Imagén por resonancia magnética | May 10, 2016 | Policy Archived | ... | Ver |
| 06.001.003 | Biopsia de Mama dirijida por MRI | May 10, 2016 | Policy Archived | ... | Ver |
